Drug intelligence / Profile preview

VTx-004

Development stage: Discontinued
Lead developer: VectorY Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intrathecal, Intravenous

Overview

VTx-004 is a vectorized antibody drug candidate that targets alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease and other synucleinopathies. The drug was initially developed by VectorY BV. Its mechanism of action involves inhibition of alpha-synuclein, aiming to reduce or prevent the aggregation and toxicity associated with this protein in neurodegenerative diseases. As of the latest available information, development of VTx-004 has been discontinued[1][4].

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on VTx-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTx-004.

Explore the full profile